





Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora Ł. Ellison Donald R. Banowit

Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Theodore A. Wood Edward W. Yee Grant E. Reed Jason D. Eisenberg Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth

August 11, 2008

Lori A. Gordon Laura A. Vogel Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz James J. Pohl John T. Haran Mark W. Rygiel Michael R. Malek* Carla Ji-Eun Kim Dylrike Winkler Jenks Paul A. Calvo C. Matthew Rozier* Randall K. Baldwin Daniel J. Nevrivy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Coller Ill*
Keisha Hylton-Rodic
Bonnie Nannenga-Combs
Ahyssa K. Sandrowitz*
Jonathan M. Strang*
Ishan P. Weerakoon*

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Peter A. Socarras Danielle L. Letting Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana Stephanie L. Elmer Robert E. Bakin Salvador M. Bezos Yasser Mourtada

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist David C. Isaacson

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: UNANSWERED INTERNET ADDRESS: CDERENZO@SKGF.COM

Art Unit 1656

Attn: Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/553,685; § 371 Date: November 1, 2006

(U.S. National Phase of PCT/US2004/008323)

For: Nogo Receptor Binding Protein

Inventors: Mi et al.

Our Ref: 2159.0440003/EJH/CLD

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. Form PTO/SB/08A (5 sheets) listing 111 documents (US22-US97 and FP24-FP69);
- 3. Form PTO/SB/08B (7 sheets) listing 63 documents (NPL33-NPL95);
- 4. Copies of cited 106 documents (FP24-FP69 and NPL33-NPL92); and
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLIC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f202.371.2540: www.skqf.com

Commissioner for Patents August 11, 2008 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Cynthia L. DeRenzo
Agent for Applicants

Registration No. 60,789

CLD:trh Enclosures 859152_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mi et al.

Appl. No.: 10/553,685 (U.S. National

Phase of PCT/US2004/008323)

§371 Date: November 1, 2006

For: Nogo Receptor Binding Protein

Confirmation No.: 4041

1656 Art Unit:

Examiner: CARLSON, Karen C.

Atty. Docket: 2159.0440003/EJH/CLD

First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on October 19, 2006 in connection with the above-captioned application.

Copies of documents FP24 to FP69 and NPL33 to NPL92 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents US22 to US97, cited on the attached IDS Form PTO/SB/08A are not submitted. In addition, copies of documents NPL93 to NPL95 are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited

pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 11/892,036, inventors Mi *et al.*, continuation of PCT/US2006/026271, international filing date July 7, 2006; and listed as document **NPL93** (NOT PUBLISHED);

Application No. 12/092,662, inventors Mi *et al.*, National Phase of PCT/US2006/042990, international filing date November 3, 2006; and listed as document **NPL94** (NOT PUBLISHED); and

Application No. 12/095,857, inventors Mi *et al.*, National Phase of PCT/US2006/045993, international filing date December 1, 2006; and listed as document **NPL95** (NOT PUBLISHED).

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Cypulus J. DeRenzo, Ph.D.

Agent for Applicants Registration No. 60,789

Date:

8 11 08

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 847249v1